14
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical
Oncology Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is
not intended to substitute for the independent professional judgment of the treating physician.
Practice guidelines do not account for individual variation among patients. is pocket guide
does not purport to suggest any particular course of medical treatment. Use of the practice
guidelines and this resource are voluntary. e practice guidelines and additional information
are available at www.asco.org/breast-cancer-guidelines. Copyright © 2018 by American Society
of Clinical Oncology. All rights reserved.
Source
Wolff AC et al. Human Epidermal Growth Factor Receptor 2 Testing In Breast Cancer:
American Society of Clinical Oncology/College of American Pathologists Clinical Practice
Guideline Focused Update. J Clin Oncol. 2018 May 30 DOI: 10.1200/JCO.2018.77.8738
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2018 All rights reserved
ASCOHER21853
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and other clinical
tools and resources, is available at www.asco.org/breast-cancer-guidelines
Abbreviations
ASCO/CAP, American Society of Clinical Oncology and College of American
Pathologists; CEP17, centromeric probe for chromosome 17; ER, estrogen receptor; FDA,
U.S. Food and Drug Administration; FISH, fluorescent in situ hybridization; HER2,
human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ
hybridization; PgR, progesterone receptor
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
FC
Formal
consensus
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient
